Johnson & Johnson (JNJ) Shares Sold by Aviva PLC

Aviva PLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,943,969 shares of the company’s stock after selling 79,237 shares during the quarter. Johnson & Johnson comprises 1.4% of Aviva PLC’s holdings, making the stock its 6th biggest position. Aviva PLC owned approximately 0.07% of Johnson & Johnson worth $257,225,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. State Street Corp boosted its position in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. Harbour Capital Advisors LLC boosted its position in Johnson & Johnson by 13,327.8% during the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after acquiring an additional 2,482,843 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in Johnson & Johnson by 33.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 4,696,566 shares of the company’s stock worth $621,309,000 after acquiring an additional 1,189,900 shares during the last quarter. Bank of Nova Scotia boosted its position in Johnson & Johnson by 94.5% during the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after acquiring an additional 569,313 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $65,598,000. Institutional investors and hedge funds own 65.91% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $139.98 on Friday. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The stock has a market capitalization of $376,059.06, a P/E ratio of 19.61, a PEG ratio of 2.84 and a beta of 0.81. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the prior year, the business posted $1.68 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

JNJ has been the subject of a number of recent research reports. Cowen reaffirmed an “outperform” rating and set a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reaffirmed a “buy” rating and set a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group upped their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $144.59.

WARNING: This piece was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/12/03/johnson-johnson-jnj-shares-sold-by-aviva-plc.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit